A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a serious form of fatty liver disease, a new study has found.

Adverse events leading to trial discontinuation were 2.6% for the semaglutide group and 3.3% for the placebo group. 1 Semaglutide 2.4 mg is not approved in the US for the treatment of MASH.

RICHMOND, Va., April 30, 2025 (GLOBE NEWSWIRE) -- An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and ...

The study’s semaglutide subjects also saw 10.5% weight loss, as well as improvements in liver enzymes and liver fibrosis measurements. How are hypertension, heart disease and stroke related?

Positive findings from a phase III trial of semaglutide in metabolic dysfunction-associated steatohepatitis (MASH) is moving Novo Nordisk A/S to expand the glucagon-like peptide-1 (GLP-1) agonist’s ...

Search for Symbols, analysts, keywords Log in ESSENCE phase 3 trial of semaglutide showed significant improvements at 72 weeks in adults with MASH, published in NEJM Apr. 30, 2025 5:31 PM ET ...

VCU-led research highlights semaglutide’s potential for treating fatty liver disease Provided by GlobeNewswire Apr 30, 2025, 10:09:48 PM ...